Recently, in the setting of lung cancer, advances in RAS variant-specific targeting have been achieved with FDA approval of sotorasib and adagrasib in patients with locally advanced or metastatic non-small cell lung cancer harboring a KRAS p.Gly12Cys variant (97, 98). Here, KRAS is linked to lung carcinoma.